World journal of urology · 1994
Management of contralateral testicular intraepithelial neoplasia in patients with testicular germ-cell tumor.
Клиническое исследованиеКонтролируемое клиническое исследованиеСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dieckmann K P, Loy V
Аннотация
Contralateral biopsies from 1810 consecutive patients with testicular germ-cell tumor were examined immunohistologically by staining for placental alkaline phosphatase. Contralateral testicular intraepithelial neoplasia (TIN; carcinoma in situ) was found in 89 patients (4.9%; 95% confidence interval, 3.9%-5.9%). Testicular atrophy was present in 45.9% of patients with TIN and in 13.1% of those without TIN (P < 0.01). There was a history of cryptorchidism in 16.2% of patients with TIN versus only 8.5% of those without TIN (P < 0.05). Patients with contralateral TIN presented at an earlier age (30.8 versus 33.3 years). In all, 23 patients with contralateral TIN had no specific risk marker. In 14 patients with contralateral TIN who had received local radiotherapy of 18-20 Gy to the testis, rebiopsy revealed the disappearance of TIN in all cases. Serum testosterone levels were within or above the normal range in 7 of 13 patients examined after local radiotherapy. Of 9 patients with contralateral TIN who had received chemotherapy, 2 were shown to have persistent TIN at rebiopsy. We conclude that all patients with testicular germ-cell tumor should be offered a contralateral biopsy. Local radiotherapy of the testis is the treatment of choice in patients with contralateral TIN.
Предметные рубрики MeSH
AdultAge FactorsAntineoplastic Combined Chemotherapy ProtocolsAustriaBiomarkers, TumorBiopsyCarcinoma in SituCisplatinCombined Modality TherapyFollicle Stimulating HormoneGermanyGerminomaHumansLuteinizing HormoneMaleNeoplasms, Multiple PrimaryPredictive Value of TestsRemission InductionRisk FactorsTesticular NeoplasmsTestisTestosteroneTreatment Outcome